Doripenem
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
Diarrhoea
|
Diarrhoea
|
common, 0.1% - 14%
|
|
x
|
x
|
x
|
Nausea
|
Nausea
|
common, 0.1% - 12%
|
|
x
|
x
|
x
|
Anaemia
|
Anaemia
|
1% - 10%
|
|
|
x
|
x
|
Headache
|
Headache
|
very common, 3% - 16%
|
|
x
|
x
|
x
|
Phlebitis
|
Phlebitis
|
common, 1% - 8%
|
|
x
|
x
|
x
|
Dermatitis
|
Rash
|
common, 0.2% - 6%
|
|
x
|
x
|
x
|
Rash
|
Rash
|
common, 0.2% - 6%
|
|
x
|
x
|
x
|
Hepatic enzyme increased
|
Hepatic enzyme increased
|
common, 0.2%
|
|
x
|
|
|
Candida infection
|
Oral candidiasis
|
common, 0% - 3%
|
|
x
|
x
|
x
|
Oral candidiasis
|
Oral candidiasis
|
common, 0% - 3%
|
|
x
|
x
|
x
|
Pruritus
|
Pruritus
|
common, 0.1% - 3%
|
|
x
|
x
|
x
|
Infection
|
Infection
|
common, 0% - 2%
|
|
x
|
x
|
x
|
Hypersensitivity
|
Hypersensitivity
|
uncommon
|
|
x
|
x
|
x
|
Clostridium difficile colitis
|
Clostridium difficile colitis
|
uncommon
|
|
x
|
|
|
Colitis
|
Colitis
|
0% - 2%
|
|
|
x
|
x
|
Thrombocytopenia
|
Thrombocytopenia
|
postmarketing, uncommon
|
|
x
|
|
x
|
Thrombocytopenia toxic
|
postmarketing
|
|
|
x
|
|
Anaphylactic shock
|
Anaphylactic shock
|
postmarketing
|
|
x
|
x
|
x
|
Toxic epidermal necrolysis
|
Toxic epidermal necrolysis
|
postmarketing
|
|
x
|
|
x
|
Necrolysis epidermal
|
postmarketing
|
|
|
x
|
|
Leukopenia
|
Leukopenia
|
postmarketing
|
|
|
x
|
x
|
Neutropenia
|
Neutropenia
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
Convulsion
|
Convulsion
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
Erythema multiforme
|
Stevens-Johnson syndrome
|
postmarketing
|
|
x
|
x
|
x
|
Stevens-Johnson syndrome
|
Stevens-Johnson syndrome
|
postmarketing
|
|
x
|
x
|
x
|
Interstitial lung disease
|
Interstitial pneumonia
|
postmarketing
|
|
|
x
|
x
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
|
|
x
|
x
|
x
|
Immune system disorder
|
Immune system disorder
|
|
|
x
|
|
|
Nervous system disorder
|
Nervous system disorder
|
|
|
x
|
x
|
x
|
Pneumonia
|
Pneumonia
|
|
|
|
x
|
x
|
Angiopathy
|
Angiopathy
|
|
|
x
|
x
|
x
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
x
|
|
|
Hepatobiliary disease
|
Hepatobiliary disease
|
|
|
x
|
|
|
Drug interaction
|
Drug interaction
|
|
|
|
x
|
x
|
Infestation
|
Infestation NOS
|
|
|
|
x
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 24 |
Source: | EMA |
---|
Side effects: | 26 |
Source: | FDA Structured Product Label |
---|
Side effects: | 26 |
Source: | FDA Structured Product Label |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|